Decreased expression of ING2 gene and its clinicopathological significance in Chinese NSCLC patients

Neoplasma
|April 10, 2014
PubMed

Insights

Inhibitor of growth 2 (ING2) protein expression is significantly decreased in non-small cell lung cancer (NSCLC). This aberrant ING2 expression, including nuclear-to-cytoplasmic translocation, may contribute to NSCLC tumorigenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The inhibitor of growth 2 (ING2) is implicated in cell cycle regulation, DNA repair, and apoptosis.
  • ING2's role in carcinogenesis varies, acting as either a tumor suppressor or oncogene.
  • Understanding ING2's expression status in lung cancer is crucial.

Purpose of the Study:

  • To investigate the expression status and potential role of ING2 in non-small cell lung cancer (NSCLC).
  • To correlate ING2 expression with clinicopathological features in NSCLC patients.

Main Methods:

  • Immunohistochemistry (IHC) was used to assess ING2 protein levels in 64 Chinese NSCLC patients and normal lung tissues.
  • Western blotting and RT-PCR were employed to confirm protein and mRNA expression levels.
  • ING2 gene sequencing was performed to detect mutations.

Main Results:

  • ING2 protein expression was significantly decreased in NSCLC tissues compared to normal lung tissues (P<0.05).
  • ING2 expression was lost in 32.8% of NSCLC cases, more prevalent in adenocarcinoma (45.8%) than squamous cell carcinoma (26.3%).
  • ING2 translocation from nucleus to cytoplasm was observed, and its status in squamous cell carcinoma correlated with lymph node metastasis and TNM stage.

Conclusions:

  • Aberrant expression of ING2, including decreased levels and cytoplasmic translocation, may contribute to NSCLC tumorigenesis.
  • ING2 alterations are frequent in NSCLC, suggesting its potential as a biomarker or therapeutic target.
  • No significant mutations or heterozygosity were found in the ING2 gene in the studied cohort.